- Home
- PENN vs GLUE Comparison
PENN vs GLUE Comparison
Compare PENN & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENN | GLUE |
|---|---|---|
| Founded | 1972 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PENN | GLUE |
|---|---|---|
| Price | $19.23 | $16.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $20.83 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 3.2M | 703.4K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,362,900,000.00 | $123,672,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | $3.83 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $11.65 | $4.12 |
| 52 Week High | $20.61 | $25.77 |
Technical Indicators
Market Signals| Indicator | PENN | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.07 | 32.79 |
| Support Level | $18.67 | $14.43 |
| Resistance Level | $20.32 | $16.66 |
| Average True Range (ATR) | 0.78 | 1.07 |
| MACD | 0.20 | -0.28 |
| Stochastic Oscillator | 71.57 | 1.22 |
Price Performance
Historical ComparisonAbout PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).